Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "Vial"

214 News Found

Corbevax receives EUA for 12-18 age group
News | February 21, 2022

Corbevax receives EUA for 12-18 age group

It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19


WHO prequalifies first monoclonal antibody - tocilizumab – to treat Covid-19
Drug Approval | February 14, 2022

WHO prequalifies first monoclonal antibody - tocilizumab – to treat Covid-19

The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification


Dr Reddy’s launch generic version of Vasostrict in the US
Drug Approval | February 09, 2022

Dr Reddy’s launch generic version of Vasostrict in the US

The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health


Lupin receives approval from USFDA for Arformoterol Tartrate inhalation
Drug Approval | February 08, 2022

Lupin receives approval from USFDA for Arformoterol Tartrate inhalation

Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)


Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
News | February 07, 2022

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Indian govt. places order for five crore doses of Corbevax
News | February 05, 2022

Indian govt. places order for five crore doses of Corbevax

Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius


USFDA approves first generic of Restasis
Drug Approval | February 03, 2022

USFDA approves first generic of Restasis

Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug


WHO recommends two new drugs for COVID-19
Drug Approval | January 14, 2022

WHO recommends two new drugs for COVID-19

Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation


Covaxin booster neutralises Omicron and Delta variants: Study
News | January 12, 2022

Covaxin booster neutralises Omicron and Delta variants: Study

The study will be published on the pre-print server, medRXiv, shortly


Covaxin booster dose study shows promising results
News | January 08, 2022

Covaxin booster dose study shows promising results

Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events